NCT06765993尚未招募2 期
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II/III Clinical Study of Isosorbide Oral Solution in the Treatment of Meniere's Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 234
- 主要终点
- The changes from baseline in the number of vertigo attacks due to Meniere's disease during the treatment period
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of isosorbide oral solution compared with placebo in people with unilateral Meniere's disease. A total of approximately 234 subjects will be enrolled in this study: 72 subjects in phase Ⅱ and approximately 162 subjects in phase Ⅲ. Patients were randomly assigned to either the experimental group or the control group. The randomization ratios for phase Ⅱ and phase Ⅲ were 1:1 and 2:1, respectively.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female aged ≥18 and ≤65 years old.
- •Patients with unilateral Meniere's disease who meet the diagnostic criteria for Meniere's disease in the Guidelines for the Diagnosis and Treatment of Meniere's Disease (2017).
- •At least 3 episodes of vertigo caused by Meniere's disease within 6 months before enrollment.
- •Those who understand and voluntarily sign the informed consent.
排除标准
- •Patients who have had previous ear surgery for Meniere's disease.
- •People who suffer from vertigo caused by organic lesions of the external, middle or inner ear.
- •Patients with diseases that the investigators believe may limit the subjects' participation in this trial:
- •patients with acute intracranial hematoma;
- •patients with hypokalemia (serum potassium < lower limit of normal) or severe dehydration (needing infusion, or hospitalization, or life-threatening, requiring emergency treatment);
- •patients with acute pulmonary edema;
- •patients with hypotension (systolic blood pressure <90 mmHg and/or diastolic blood pressure <60 mmHg during the screening period);
- •patients with severe cardiovascular and cerebrovascular diseases: such as New York Heart Association grade III or IV heart failure, myocardial infarction or unstable angina pectoris within the last 6 months, severe heart failure, progressive multifocal leukoencephalopathy, hypertension that is difficult to control with drugs (systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥100 mmHg), etc.;
- •patients with major diseases of other important organs that affect their participation in this study.
- •Patients who need to use diuretics other than trial drugs for a long time after enrollment.
- •Patients with any of the following conditions are known or found in laboratory tests:
- •serum creatinine (Cr) level is not within the normal range;
- •human immunodeficiency virus (HIV) test is positive or has acquired immunodeficiency syndrome (AIDS);
- •active syphilis infection (positive Treponema pallidum antibody and positive non-specific syphilis antibody);
- •active hepatitis, hepatitis B: HBsAg and/or HBcAb are positive and HBV-DNA > 500 IU/mL or the lower limit of detection of the research center [only when the lower limit of detection of the research center is higher than 500 IU/mL]; hepatitis C: HCV antibody is positive and HCV-RNA is positive or greater than the upper limit of normal value.
- •Patients with known or suspected history of allergy to the investigational drug (isosorbide) and its excipients (sorbitol, lactic acid, saccharin sodium, propylparaben, butylparaben, orange flavor).
- •Those with a history of drug abuse or alcoholism within 6 months before enrollment.
- •Patients who have taken any prohibited drugs specified in this protocol for more than 1 week within 4 weeks before the first administration, including but not limited to vestibular suppressants (including antihistamines - promethazine, diphenhydramine, chlorpheniramine, etc., benzodiazepines - diazepam, lorazepam, clonazepam, etc., anticholinergics - scopolamine, atropine, glycopyrrolate, etc., and antidopamines - prochlorperazine, droperidol, etc.), betahistine, diuretics (including thiazide diuretics - hydrochlorothiazide, chlorthalidone, indapamide, indapamide sustained-release tablets, etc., loop diuretics - furosemide, torsemide, etc., potassium-sparing diuretics - amiloride, triamterene, etc.), glucocorticoids (including prednisone, methylprednisolone, betamethasone, beclomethasone propionate, prednisolone, hydrocortisone, dexamethasone, etc.).
- •Those who received intratympanic injection of gentamicin within the last year.
- •Patients who have received any other clinical trial drugs/devices within 30 days before the first dose.
- •Pregnant or lactating women, female patients or male patients' partners who plan to become pregnant during the study period and within 6 months after the last dose, and those who are unwilling to use a medically recognized effective contraceptive method (such as intrauterine contraceptive device or condom) during the trial.
- •Those who are judged by the researchers to be unsuitable for inclusion.
研究组 & 干预措施
Experimental group
Experimental
干预措施: Isosorbide oral solution (Drug)
Control group
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
The changes from baseline in the number of vertigo attacks due to Meniere's disease during the treatment period
时间窗: 3 months
次要结局
- The changes in the number of vertigo attacks caused by Meniere's disease compared with the baseline at 6 months after the first administration.(6 months after the first administration)
- The changes in the number of vertigo attacks caused by Meniere's disease compared with the baseline at 4-6 months after the first administration.(4-6 months after the first administration)
- The changes in hearing from baseline 6 months after the first dose.(6 months after first dose)
- Patient-reported outcomes (PRO) during the treatment period were assessed using the Dizziness Handicap Inventory (DHI).(3 months after the first dose)
- Patient-reported outcomes (PRO) during the treatment period were assessed using the Tinnitus Handicap Inventory (THI).(3 months after the first dose)
- Patient-reported outcomes (PRO) were assessed using the Dizziness Handicap Inventory (DHI) at 6 months after the first dose.(6 months after the first dose)
- Patient-reported outcomes (PRO) were assessed using the Tinnitus Handicap Inventory (THI) at 6 months after the first dose.(6 months after the first dose)
研究者
相似试验
撤回
4 期
Intravenous Isosorbide Dinitrate Versus Sublingual Isosorbide Dinitrate for the Relief of Acute Anginal Episodes in Acute Coronary Syndrome (ACS) PatientsMyocardial InfarctionUnstable AnginaNCT00337116Soroka University Medical Center80
已完成
2 期
Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)Irritable Bowel Syndrome With ConstipationNCT00460811Ironwood Pharmaceuticals, Inc.420
撤回
1 期
PK, PD and Safety Comparative Trial of Isosorbide Mononitrate Gel in Healthy Participants and With Anal FissureAnal FissureNCT02667535Biolab Sanus Farmaceutica
已完成
2 期
Trial to Determine the Safety of Oral Ifetroban in Patients With a History of Aspirin Exacerbated Respiratory DiseaseAspirin Exacerbated Respiratory Disease (AERD)NCT02216357Cumberland Pharmaceuticals19
已完成
早期 1 期
Efficacy and Safety of Topiramate in the Treatment of Sleep-Related Eating DisorderSleep-Related Eating DisorderNCT00606411Massachusetts General Hospital34